S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:EIGR

Eiger BioPharmaceuticals Stock Forecast, Price & News

$5.86
-0.41 (-6.54%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.85
$6.22
50-Day Range
$5.77
$8.19
52-Week Range
$5.74
$13.49
Volume
214,927 shs
Average Volume
166,927 shs
Market Capitalization
$199.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.32
30 days | 90 days | 365 days | Advanced Chart
Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eiger BioPharmaceuticals logo

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EIGR
Employees
28
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.63 per share

Profitability

Net Income
$-65.05 million
Pretax Margin
-351.96%

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,734,000
Market Cap
$199.12 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/05/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

460th out of 1,388 stocks

Biological Products, Except Diagnostic Industry

73rd out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

Is Eiger BioPharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals
or view top-rated stocks.

How has Eiger BioPharmaceuticals' stock price been impacted by COVID-19?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EIGR stock has decreased by 14.0% and is now trading at $5.86.
View which stocks have been most impacted by COVID-19
.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Eiger BioPharmaceuticals
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.07. The biotechnology company earned $3.04 million during the quarter, compared to the consensus estimate of $2.54 million. During the same period last year, the company posted ($0.52) EPS.
View Eiger BioPharmaceuticals' earnings history
.

What price target have analysts set for EIGR?

3 Wall Street analysts have issued 1 year price objectives for Eiger BioPharmaceuticals' stock. Their forecasts range from $22.00 to $45.00. On average, they expect Eiger BioPharmaceuticals' share price to reach $31.33 in the next twelve months. This suggests a possible upside of 434.7% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:
  • David A. Cory, President, Chief Executive Officer & Director
  • Sriram Ryali, Chief Financial Officer
  • Ingrid C. Choong, Senior Vice President-Clinical Development
  • Colin Hislop, Senior VP-Clinical & Development Operations
  • Chris Dadas, Vice President-Medical Affairs

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (9.34%), BlackRock Inc. (7.28%), Geode Capital Management LLC (1.79%), Goldman Sachs Group Inc. (1.12%), Knott David M (0.92%) and Dimensional Fund Advisors LP (0.62%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Evan Loh, Jeffrey S Glenn and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals
.

Which major investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Goldman Sachs Group Inc., California State Teachers Retirement System, New York State Common Retirement Fund, Two Sigma Investments LP, Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Eiger BioPharmaceuticals company stock in the last year include Eldon C Mayer III, and Evan Loh.
View insider buying and selling activity for Eiger BioPharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Renaissance Technologies LLC, GSA Capital Partners LLP, Jane Street Group LLC, Sigma Planning Corp, Apis Capital Advisors LLC, Telemetry Investments L.L.C., and Dupont Capital Management Corp. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $5.86.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals has a market capitalization of $199.12 million. The biotechnology company earns $-65.05 million in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does Eiger BioPharmaceuticals have?

Eiger BioPharmaceuticals employs 28 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Where are Eiger BioPharmaceuticals' headquarters?

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at (650) 272-6138, via email at [email protected], or via fax at 650-618-1621.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.